Royalton Chic Resorts to Debut in Jamaica, Set to Redefine Adults-Only Lifestyle Getaways
BERLIN, March 10, 2025 (GLOBE NEWSWIRE) -- In the midst of ITB Berlin, Blue Diamond Resorts is unveiling its latest venture in the Caribbean: Royalton CHIC Jamaica Paradise Cove, An Autograph Collection All Inclusive Resort – Adults Only, set to debut in late 2026. Building on the success of Royalton CHIC Resorts in Cancun, Punta Cana, Antigua and the upcoming resort in Barbados, this highly anticipated opening will bring the brand's signature blend of sophistication, trendiness, and vibrant social experiences to Jamaica for the first time.
'Our expansion into Jamaica represents the remarkable success of Royalton CHIC Resorts and its impact on the all-inclusive industry and immersive hospitality,' said Jordi Pelfort, President of Blue Diamond Resorts. 'This latest development underscores the strength of our brand, the confidence of our guests, partners, and our commitment to expanding our footprint in key destinations. We continue to push boundaries, curating exceptional resorts in the most desirable beachfront locations.'
Located just one hour from Montego Bay's Sangster International Airport and forty minutes from Ocho Rios International Airport, this vibrant resort will be nestled in the coveted Runaway Bay, a serene enclave of unspoiled coastline known for its breathtaking beauty, private coves, and turquoise waters. Designed to embody the bold yet elegant vibe of Royalton CHIC Resorts, the upcoming property will feature 345 meticulously designed suites. For those looking to elevate their stay, select room categories will offer the exclusive Diamond Club™ experience, featuring premium perks such as personal butler service, elevated food and drinks, seamless check-in, enhanced in-suite amenities and exclusive access to private areas within the resort.
Guests will also enjoy four specialty à la carte restaurants, an international buffet, a Jerk Hut, and a sports bar & lounge, offering an array of world-class culinary experiences to suit every taste.
The resort's immersive entertainment experiences will come to life through sparkling happenings, featuring vibrant events and performances led by the iconic CHIC Angels. Staying true to the 'Party Your Way' philosophy, guests will have the freedom to curate their ideal getaway—whether it's unwinding in a serene beachfront retreat, indulging in world-class gastronomy, or embracing the resort's lively social scene.
As part of Marriott International's prestigious Autograph Collection, Royalton CHIC Jamaica Paradise Cove will offer a distinctive fusion of posh hospitality and signature social experiences, ensuring guests enjoy an unparalleled level of service, style, and exclusivity.
With its modern aesthetic, sophisticated ambiance, and elevated yet playful atmosphere, Royalton CHIC Resorts appeal to discerning travelers seeking more than just a traditional adults-only escape. This latest expansion further solidifies Blue Diamond Resorts' commitment to crafting premier, all-inclusive experiences in the Caribbean's most prestigious destinations.
For more information about Blue Diamond Resorts and Royalton CHIC Resorts, visit www.bluediamondresorts.com and www.royaltonchicresorts.com.
About Blue Diamond Resorts
Blue Diamond Resorts encompasses over 80 properties, exceeding 20,000 rooms in eight countries located in the most popular holiday destinations in the Caribbean. Its nine leading hotel brands include the Award-winning, All-In Luxury® Royalton Luxury Resorts, where Everyone is Family. Whether guests come as friends, parents, kids, couples, weddings, corporate or incentive retreats, or solo travelers everyone is family in these properties that feature personalized services and signature amenities including All-In Connectivity™, DreamBed™, and the Sports Event Guarantee™. To refocus on valued relationships and friendships, Hideaway at Royalton offers an adults-only experience with exclusive dining and preferred accommodations to enhance Togetherness among their guests. Party Your Way at Royalton CHIC Resorts, an adults-only vibrant and effervescent all-inclusive brand to revel in the unexpected. Mystique by Royalton is Miles from Ordinary, offering their visitors the chance to connect with their surroundings in a boutique-style resort collection full of endless beauty and hip vibes. In Jamaica, Grand Lido Negril offers guests over the age of 21, a unique and all-inclusive Au Naturel vacation along with a secluded shore for the utmost privacy. Memories Resorts & Spa offers a vacation designed whether you´re planning a family vacation, reuniting with friends, or just have a relaxing moment with your significant other, while Starfish Resorts provides amazing value, breathtaking surroundings, and rich culture and heritage. Planet Hollywood Hotels & Resorts invites guests to Vacation Like A Star™ with an engaging and interactive experience, plus famous pop culture items from iconic movies, music, and sports while you will Dodge the Paparazzi at Planet Hollywood Adult Scene where your adults-only vacation will be the center of fascination and attention with glam and exclusivity.
To learn more about Blue Diamond Resorts, please visit www.bluediamondresorts.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c24b0caf-aff8-459b-acb2-d6cb5ba3f906
CONTACT: For more information, contact media@bluediamondresorts.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio
Business Wire
8 hours ago
- Business Wire
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
HOUSTON--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. 'We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations,' said Ketjen's Chief Commercial Officer Henri Tausch. 'This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers.' 'SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon,' said David Leach, Vice President and General Manager, FCC at Ketjen. 'It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement.' Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit
